Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2022 Annual Meeting of Stockholders of Aerie Pharmaceuticals, Inc. (the "Company"), held on June 9, 2022, the Company's stockholders considered and voted upon the following proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2022:

Proposal 1: Elections of Directors.

By vote reflected below, each of the following director nominees was elected to serve on the Board of Directors for a three-year term, or until his successor has been duly elected and qualified.



Nominee                    Votes For    Votes Withheld   Broker Non-Votes
Richard Croarkin           27,422,591     1,670,508         4,683,691

Peter J. McDonnell, M.D. 27,959,224 1,133,875 4,683,691

Proposal 2: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.

By vote reflected below, the appointment of PricewaterhouseCoopers LLP was ratified.



Votes For    Votes Against   Votes Abstained
33,444,940      310,980          20,870

Proposal 3: To approve, by a non-binding vote, the compensation of the Company's named executive officers ("say-on-pay").

By vote reflected below, the Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.

Votes For Votes Against Votes Abstained Broker Non-Votes 25,798,834 3,268,573 25,692

           4,683,691

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses